<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26979433</article-id><article-id pub-id-type="pmc">4791768</article-id><article-id pub-id-type="publisher-id">1261</article-id><article-id pub-id-type="doi">10.1186/s13063-016-1261-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Beneficial effect of xylose consumption on postprandial hyperglycemia in Korean: a randomized double-blind, crossover design</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jun</surname><given-names>Yun Ju</given-names></name><address><email>hyukhg@daum.net</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lee</surname><given-names>Jinhee</given-names></name><address><email>jhlee81@cha.ac.kr</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Hwang</surname><given-names>Sehee</given-names></name><address><email>hsehee@gmail.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Kwak</surname><given-names>Jung Hyun</given-names></name><address><email>hyun4615@hanmail.net</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Hyeon Yeong</given-names></name><address><email>vitaminahy@naver.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Bak</surname><given-names>Youn Kyung</given-names></name><address><email>ykbak16@cj.net</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Koh</surname><given-names>Jihoon</given-names></name><address><email>jhkoh@cj.net</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Jong Ho</given-names></name><address><phone>+82-2-2123-3122</phone><email>jhleeb@yonsei.ac.kr</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff5"/></contrib><aff id="Aff1"><label/>Department of Food and Nutrition, National Research Laboratory for Clinical Nutrigenetics/Nutrigenomics, Yonsei University, Sudamun-Gu, Seoul Republic of Korea </aff><aff id="Aff2"><label/>Department of Food Science and Biotechnology, CHA University, Pocheon-si, Gyeonggi-do Republic of Korea </aff><aff id="Aff3"><label/>College of Pharmacy, Chung-Ang University, Dongjak-gu, Seoul Republic of Korea </aff><aff id="Aff4"><label/>Department of Preventive Medicine, Gachon University College of Medicine, Yeonsu-gu, Incheon Republic of Korea </aff><aff id="Aff5"><label/>Department of Food and Nutrition, Research Institute of Science for Aging, Yonsei University, Seodaemun-gu, Seoul Republic of Korea </aff><aff id="Aff6"><label/>Food Ingredients R&#x00026;D Center, CJ Cheiljedang Co., Suwon-si, Gyeonggi-do Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>17</volume><elocation-id>139</elocation-id><history><date date-type="received"><day>27</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Jun et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Previous studies have reported that xylose selectively inhibited the activity of sucrase. Xylose supplementation may have a beneficial effect on the postprandial glycemic response. However, no studies have investigated patients with IFG or the effectivity of a dose of D-xylose less than 10&#x000a0;% (w/w).</p></sec><sec><title>Methods</title><p>The present study determined the effect of xylose consumption on postprandial hyperglycemia in normal (n&#x02009;=&#x02009;25) and hyperglycemic subjects (n&#x02009;=&#x02009;50). Subjects in this double-blind crossover design study were randomly assigned to consume a sucrose drink (Control, sucrose 50&#x000a0;g&#x02009;+&#x02009;deionized water 100&#x000a0;g) or a sucrose drink additionally containing 5&#x000a0;g (Test 1, sucrose:xylose&#x02009;=&#x02009;10:1), 3.33&#x000a0;g (Test 2, sucrose:xylose&#x02009;=&#x02009;15:1), or 2.5&#x000a0;g (Test 3, sucrose:xylose&#x02009;=&#x02009;20:1) of D-xylose separated by a one-week interval.</p></sec><sec><title>Results</title><p>Normal subjects in all test groups exhibited a significant decrease in serum glucose levels 15&#x000a0;min and 30&#x000a0;min after consuming the xylose-containing drinks compared to the control group. Significantly lower serum levels of insulin were observed at 15&#x000a0;min and 30&#x000a0;min after consuming the xylose-containing drinks compared to the control group. The test 1 group also exhibited a significantly lower insulin area under the curve than the control group. Hyperglycemic subjects (n&#x02009;=&#x02009;50) in all test groups exhibited a significant decrease in serum glucose levels at 30&#x000a0;min compared to the control group. However, the test 1 group exhibited a significant increase in serum glucose levels at 120&#x000a0;min compared to the control group. Glucose-related markers did not significantly differ in each group.</p></sec><sec><title>Conclusion</title><p>Xylose supplementation may exert a beneficial effect on postprandial glycemic responses in subjects with normal glucose levels and prediabetes.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT02654301">NCT02654301</ext-link>. Registered 12 January 2016.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Xylose</kwd><kwd>Prediabetes</kwd><kwd>Postprandial hyperglycemia</kwd><kwd>Glucose</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Data from the 2010 Korea National Health and Nutrition Examination Survey (KNHANES) reported that the dietary total saccharide intake (61.4&#x000a0;g/day) increased by 23&#x000a0;% compared to the 2008 KNHANES report [<xref ref-type="bibr" rid="CR1">1</xref>]. The prevalence of impaired fasting glucose (IFG) in Koreans aged greater than 30&#x000a0;years has also increased consistently in the past three years [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Elevated postprandial blood glucose (PPBG) has been associated with an increased risk of metabolic disorders, type 2 diabetes, and cardiovascular disease (CVD) [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, strategies to reduce PPBG are very important.</p><p>Sugar is the most widely and commonly used sweetener worldwide, and various sweeteners, such as sugar alcohols, aspartame, and acesulfame potassium, were developed to substitute for sugar, the consumption of which is a potential reason for the rise in obesity and diabetes rates [<xref ref-type="bibr" rid="CR6">6</xref>]. However, sugar alcohols cause cramping, bloating, and diarrhea in excessive amounts [<xref ref-type="bibr" rid="CR7">7</xref>], and aspartame may be harmful to patients with phenylketonuria because of the generation of phenylalanine after consumption [<xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, these alternative sweeteners are limited as sugar substitutes.</p><p>Sucrase hydrolyzes sugar (sucrose) to glucose and fructose, which are rapidly absorbed into the blood via facilitated diffusion and active transport. Glucose absorption into the blood promotes insulin secretion, which promotes blood glucose migration into cells, generates energy, or promotes storage in the liver and muscle as glycogen [<xref ref-type="bibr" rid="CR9">9</xref>]. However, the increase in blood glucose by sugar intake may burden the pancreas of subjects with IFG, and the consequent pancreatic damage reduces insulin secretion [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Xylose is a naturally occurring monosaccharide that is primarily found in wood, and D-xylose selectively inhibits sucrase activity. Therefore, D-xylose could prevent the rise in blood glucose and insulin, which would also decrease the burden on the pancreas [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Asano et al. reported that the consumption of a sucrose drink containing 10&#x000a0;% (w/w) D-xylose suppressed the rapid elevation of blood glucose and insulin in mice [<xref ref-type="bibr" rid="CR12">12</xref>]. A sucrose drink containing 10&#x000a0;% (w/w) D-xylose also reduced the glycemic index (GI) by 21.4&#x000a0;% and insulin secretion by 21.3&#x000a0;% in healthy individuals [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>However, no studies investigated subjects with IFG and the effectivity of a dose of D-xylose less than 10&#x000a0;% (w/w). The current study assesses the acute effect of xylose on postprandial glycemia in subjects with normal glucose levels or prediabetics who consumed sucrose drinks that contained 5&#x000a0;g (Test 1; sucrose:xylose&#x02009;=&#x02009;10:1), 3.33&#x000a0;g (Test 2; sucrose:xylose&#x02009;=&#x02009;15:1), or 2.5&#x000a0;g (Test 3; sucrose:xylose&#x02009;=&#x02009;20:1) of D-xylose with a one-week separation interval.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study subjects</title><p>We posted advertisements in the local newspaper to recruit study subjects, and all clinical tests were conducted in the Clinical Nutrition Research Laboratory at Yonsei University. All study subjects aged 20 to 70&#x000a0;years were classified into two groups, normal and IFG, based on serum glucose levels. Subjects were excluded for the following reasons: 1) history of taking insulin injections or oral hypoglycemic agents, 2) evidence of alcohol abuse or alcoholism, 3) pregnant or breastfeeding, 4) chronic gastrointestinal disorder, 5) seriously abnormal liver or renal function, or 6) an occupation at risk of death when hypoglycemia occurs. A fasting serum glucose level between 100 and 125&#x000a0;mg/dL was defined as IFG. Subjects with fasting glucose levels over 126&#x000a0;mg/dL were newly diagnosed with type 2 diabetes. The Institutional Review Board of Yonsei University approved this study (IRB 163&#x02013;02), and all participants provided written informed consent. A total of 80 subjects were initially enrolled. Two participants dropped out of the study for personal reasons, and three participants discontinued the study because they were terrified during blood collection. A final total of 25 normal subjects and 50 hyperglycemic subjects were analyzed in this study.</p></sec><sec id="Sec4"><title>Study design</title><p>We adopted a randomized double-blind, crossover design to determine an effective proportion of D-xylose. All study subjects were randomly assigned using the random assignment table: for the consumption order of four drinks provided by CJ Cheiljedang Co., Ltd. (Guro-Gu, Seoul). The experimental drinks were indistinguishable from each other and included: 1) Control (sucrose 50&#x000a0;g&#x02009;+&#x02009;deionized water 100&#x000a0;g), 2) Test 1 (sucrose:xylose&#x02009;=&#x02009;10:1, sucrose 50&#x000a0;g&#x02009;+&#x02009;xylose 5&#x000a0;g&#x02009;+&#x02009;deionized water 95&#x000a0;g), 3) Test 2 (sucrose:xylose&#x02009;=&#x02009;15:1, sucrose 50&#x000a0;g&#x02009;+&#x02009;xylose 3.33&#x000a0;g&#x02009;+&#x02009;deionized water 96.67&#x000a0;g), and 4) Test 3 (sucrose:xylose&#x02009;=&#x02009;20:1, sucrose 50&#x000a0;g&#x02009;+&#x02009;xylose 2.5&#x000a0;g&#x02009;+&#x02009;deionized water 97.5&#x000a0;g).</p><p>Subjects visited the Clinical Nutrition Research Laboratory at Yonsei University for 4&#x02013;5 weeks and randomly ingested the four test drinks (Control, Test 1, Test 2, and Test 3) with a one-week interval to avoid a carryover effect, which is the persistence and influence of the previous treatment on the following treatment in a crossover design trial [<xref ref-type="bibr" rid="CR14">14</xref>]. We also asked the subjects to maintain their usual diet and physical activity until the end of the study.</p></sec><sec id="Sec5"><title>Anthropometric parameters, blood pressure measurement, and blood collection</title><p>The body weight of barefoot subjects was measured on the morning of each visit to obtain the body mass index (BMI, kg/m<sup>2</sup>), which was calculated as body weight (kg) divided by height squared (m<sup>2</sup>). Body fat (%) was determined using a bioelectrical impedance analyzer (InnerScan BC-533, Tanita, Japan), and lean body mass (kg) was calculated using weight (kg) and body fat (%). We also measured waist circumference at the umbilical region and hip circumference at the protruding part of the hip in standing subjects.</p><p>Blood pressure (BP) was measured twice in the upper arm after a 5-min rest using a non-invasive blood pressure monitor (EASY X 800, Jawon Medical, Republic of Korea). The average of two BP measurements was recorded. BP was measured a third time when the difference between the two BP measurements was greater than 10&#x000a0;mmHg.</p><p>Venous blood specimens were collected in EDTA-treated and plain tubes at five time points: after fasting for 12&#x000a0;h, and 15, 30, 60, and 120&#x000a0;min after the consumption of each test drink. All blood samples were centrifuged to obtain plasma and sera, which were stored in a &#x02212;70&#x000a0;&#x000b0;C deep freezer until analysis.</p></sec><sec id="Sec6"><title>Assessments of dietary intake and physical activity</title><p>We investigated subjects&#x02019; usual food intake using a 24-h recall method and semi-quantitative food frequency questionnaire (semi-FFQ) during their first visit and instructed participants not to change their usual diet and level of physical activity to avoid any effects on their health and biochemical parameters.</p><p>Total calorie intake (TCI, kcal/day), the percentage of calories from carbohydrates, protein, and fat, and the amount of cholesterol in their diet (mg/day) were evaluated using the Computer-Aided Nutritional analysis program (CAN-pro 3.0, Korean Nutrition Society, Korea). Total energy expenditure (TEE, kcal/day) was calculated from the basal metabolic rate (BMR), the 24-h physical activity [<xref ref-type="bibr" rid="CR15">15</xref>], and the thermic effect of food (TEF). The BMR of each subject was calculated using the Harris&#x02013;Benedict equation [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec7"><title>Fasting and postprandial glucose, insulin, C-peptide, and FFA concentrations</title><p>Venous blood was drawn after a 12-h fast and 15, 30, 60, and 120&#x000a0;min after the consumption of test drinks. The hexokinase method colorimetrically measured NADP to determine fasting and postprandial glucose concentrations in sera using a clinical chemistry analyzer (Hitachi 7600 Autoanalyzer, Hitachi Ltd., Japan). Serum insulin and C-peptide levels were analyzed using commercially available radioimmunoassay (RIA) kits and a gamma counter (Cobra Quantum 5002, Hewlett-Packard, USA). Free fatty acids (FFAs) were measured using an enzymatic method involving acyl-CoA synthetase (ACS) and acyl-CoA oxidase (ACOD).</p></sec><sec id="Sec8"><title>Serum lipid profiles and apolipoproteins A-I and B</title><p>Fasting triglyceride and total cholesterol concentrations (mg/dL) in sera were measured using enzymatic methods in a clinical chemistry analyzer (Hitachi 7600 Autoanalyzer, Hitachi Ltd., Japan). High-density lipoprotein (HDL) cholesterol (mg/dL) was analyzed in the supernatant using selective inhibition methods after combination with chylomicrons. Low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) were combined with surfactants. Low-density lipoprotein (LDL) cholesterol (mg/dL) was estimated indirectly using the Friedewald formula. Immunoturbidimetric methods were used to determine serum apolipoproteins A-I and B (mg/dL) using a chemical analyzer (Cobas Integra 400, Roche, Switzerland).</p></sec><sec id="Sec9"><title>Safety parameters</title><p>The International Federation of Clinical Chemistry (IFCC) recommends the measurement of serum glutamic oxaloacetic transaminase (sGOT or AST) and glutamic pyruvic transaminase (sGPT or ALT) using a kinetic UV method and commercial kits (Roche, Germany) on a chemical analyzer (Hitachi 7600 Autoanalyzer, Hitachi Ltd., Japan). A kinetic UV assay and a colorimetric method, specifically the Jaffe reaction, were used to measure serum creatinine and blood urea nitrogen (BUN), respectively.</p><p>A complete blood count (CBC) of white blood cells (10<sup>3</sup>/mm<sup>3</sup>), red blood cells (10<sup>6</sup>/mm<sup>3</sup>), hemoglobin (g/dL), hematocrit (%), and platelets (10<sup>3</sup>/mm<sup>3</sup>) was performed using a hematology analyzer (ABX Micros ES 60, HORIBA ABX Diagnostics, Inc., France).</p></sec><sec id="Sec10"><title>Statistical methods</title><p>Statistical analyses were performed using SPSS version 18.0 for Windows (Statistical Package for Social Science, SPSS Inc., USA). Each variable was examined for normal distribution, and significantly skewed variables underwent log transformation. The mean values of untransformed variables are presented for descriptive purposes. Baseline characteristics and comparisons between the normal and hyperglycemic groups were evaluated using Student&#x02019;s <italic>t</italic>-test for continuous variables. Glucose, insulin, and C-peptide areas under the curve (AUCs) were calculated after subtraction of the baseline value from each subsequent measurement using the trapezoidal method [<xref ref-type="bibr" rid="CR17">17</xref>]. Comparisons between the consumption of the control drink (sucrose 50&#x000a0;g&#x02009;+&#x02009;deionized water 100&#x000a0;g) and each test drink (Test 1: sucrose:xylose&#x02009;=&#x02009;10:1, Test 2: sucrose:xylose&#x02009;=&#x02009;15:1, Test 3: sucrose:xylose&#x02009;=&#x02009;20:1) were evaluated using one-way analysis of variance (ANOVA) and Bonferroni methods at each time point. Only results from participants who completed the intervention program were analyzed. The results are expressed as the means&#x02009;&#x000b1;&#x02009;standard error of the mean (SEM). We considered results with a <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.05 as statistically significant and results with a <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.1 to exhibit a tendency toward significance.</p></sec></sec><sec id="Sec11" sec-type="results"><title>Results</title><sec id="Sec12"><title>Characteristics of normal and prediabetic subjects</title><p>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> shows the general characteristics of the study subjects. Hyperglycemic subjects were older (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and had higher concentrations of triglycerides and Apo B than normal subjects. Normal subjects exhibited a higher TEE (kcal/d) than hyperglycemic subjects. There were no significant differences between the two groups in baseline characteristics, such as BMI, body fat, blood pressure, HDL cholesterol, LDL cholesterol, Apo A-I, total energy intake, and the percent energy intake from carbohydrate, protein, and fat.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of study participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Normal subjects<break/>(n&#x02009;=&#x02009;25)</th><th>Hyperglycemic subjects<break/>(n&#x02009;=&#x02009;50)</th><th>
<italic>p</italic>-value</th></tr></thead><tbody><tr><td>n (male/female)</td><td>(13/12)</td><td>(35/15)</td><td/></tr><tr><td>Age (years)</td><td>28.2&#x02009;&#x000b1;&#x02009;1.12</td><td>50.1&#x02009;&#x000b1;&#x02009;1.80</td><td>&#x0003c;0.0001</td></tr><tr><td>Weight (kg)</td><td>69.5&#x02009;&#x000b1;&#x02009;2.83</td><td>67.7&#x02009;&#x000b1;&#x02009;1.48</td><td>0.053</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>23.8&#x02009;&#x000b1;&#x02009;0.72</td><td>24.4&#x02009;&#x000b1;&#x02009;0.46</td><td>0.453</td></tr><tr><td>Body fat (%)<sup>a</sup>
</td><td>25.1&#x02009;&#x000b1;&#x02009;1.24</td><td>25.0&#x02009;&#x000b1;&#x02009;1.07</td><td>0.742</td></tr><tr><td>Lean body mass (kg)<sup>a</sup>
</td><td>52.1&#x02009;&#x000b1;&#x02009;2.29</td><td>50.6&#x02009;&#x000b1;&#x02009;1.18</td><td>0.672</td></tr><tr><td colspan="3">Blood pressure (mmHg)</td><td/></tr><tr><td>&#x02003;Systolic BP</td><td>119.2&#x02009;&#x000b1;&#x02009;3.45</td><td>122.0&#x02009;&#x000b1;&#x02009;2.08</td><td>0.470</td></tr><tr><td>&#x02003;Diastolic BP<sup>a</sup>
</td><td>72.1&#x02009;&#x000b1;&#x02009;2.38</td><td>74.4&#x02009;&#x000b1;&#x02009;1.42</td><td>0.315</td></tr><tr><td colspan="4">Lipids parameters</td></tr><tr><td>&#x02003;TG (mg/dL)<sup>a</sup>
</td><td>92.3&#x02009;&#x000b1;&#x02009;8.95</td><td>133.1&#x02009;&#x000b1;&#x02009;11.58</td><td>0.010</td></tr><tr><td>&#x02003;T chol (mg/dL)</td><td>182.8&#x02009;&#x000b1;&#x02009;6.32</td><td>196.4&#x02009;&#x000b1;&#x02009;4.33</td><td>0.077</td></tr><tr><td>&#x02003;HDL chol (mg/dL)</td><td>57.4&#x02009;&#x000b1;&#x02009;1.91</td><td>53.5&#x02009;&#x000b1;&#x02009;1.43</td><td>0.108</td></tr><tr><td>&#x02003;LDL chol (mg/dL)</td><td>106.9&#x02009;&#x000b1;&#x02009;5.26</td><td>116.5&#x02009;&#x000b1;&#x02009;3.92</td><td>0.155</td></tr><tr><td>&#x02003;Apo A-I (mg/dL)</td><td>156.1&#x02009;&#x000b1;&#x02009;3.52</td><td>149.7&#x02009;&#x000b1;&#x02009;3.03</td><td>0.204</td></tr><tr><td>&#x02003;Apo B (mg/dL)<sup>a</sup>
</td><td>90.5&#x02009;&#x000b1;&#x02009;5.12</td><td>105.5&#x02009;&#x000b1;&#x02009;3.19</td><td>0.014</td></tr><tr><td colspan="4">Dietary intake and total energy expenditure</td></tr><tr><td>&#x02003;TEE (kcal/d)</td><td>2437&#x02009;&#x000b1;&#x02009;70.8</td><td>2281&#x02009;&#x000b1;&#x02009;37.5</td><td>0.036</td></tr><tr><td>&#x02003;TCI (kcal/d)</td><td>2315&#x02009;&#x000b1;&#x02009;70.7</td><td>2272&#x02009;&#x000b1;&#x02009;36.5</td><td>0.547</td></tr><tr><td>&#x02003;Carbohydrate (%)</td><td>61.7&#x02009;&#x000b1;&#x02009;0.16</td><td>61.6&#x02009;&#x000b1;&#x02009;0.11</td><td>0.558</td></tr><tr><td>&#x02003;Protein (%)</td><td>15.9&#x02009;&#x000b1;&#x02009;0.08</td><td>15.9&#x02009;&#x000b1;&#x02009;0.05</td><td>0.697</td></tr><tr><td>&#x02003;Fat (%)</td><td>23.1&#x02009;&#x000b1;&#x02009;0.20</td><td>23.0&#x02009;&#x000b1;&#x02009;0.15</td><td>0.812</td></tr><tr><td>&#x02003;Cholesterol (mg)</td><td>188&#x02009;&#x000b1;&#x02009;0.50</td><td>186&#x02009;&#x000b1;&#x02009;0.70</td><td>0.130</td></tr></tbody></table><table-wrap-foot><p>Mean&#x02009;&#x000b1;&#x02009;SEM</p><p>
<sup>a</sup>Analyzed after log transformation; tested by Student <italic>t</italic>-test</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Effects of xylose consumption on postprandial glucose metabolism in normal subjects</title><p>Normal subjects (n&#x02009;=&#x02009;25) in all test groups exhibited a significant decrease in serum glucose levels at 15&#x000a0;min (Test 1: 102.3&#x02009;&#x000b1;&#x02009;2.39, Test 2: 104.1&#x02009;&#x000b1;&#x02009;2.76, Test 3: 107.3&#x02009;&#x000b1;&#x02009;2.81 versus Control: 120.8&#x02009;&#x000b1;&#x02009;3.42&#x000a0;mg/dL) and 30&#x000a0;min (Test 1: 113.8&#x02009;&#x000b1;&#x02009;2.40, Test 2: 116.5&#x02009;&#x000b1;&#x02009;2.84, Test 3: 118.2&#x02009;&#x000b1;&#x02009;3.37 versus Control: 132.8&#x02009;&#x000b1;&#x02009;3.74&#x000a0;mg/dL) than the control group (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). However, normal subjects exhibited a significant increase in serum glucose levels in all test groups at 120&#x000a0;min compared to the control group. All test groups also exhibited significantly lower serum levels of insulin at 15&#x000a0;min (Test 1: 28.3&#x02009;&#x000b1;&#x02009;5.19, Test 2: 24.8&#x02009;&#x000b1;&#x02009;3.47, Test 3: 31.4&#x02009;&#x000b1;&#x02009;4.05 versus Control: 56.6&#x02009;&#x000b1;&#x02009;7.18 uIU/mL) and 30&#x000a0;min (Test 1: 30.4&#x02009;&#x000b1;&#x02009;3.63, Test 2: 31.0&#x02009;&#x000b1;&#x02009;3.59, Test 3: 35.9&#x02009;&#x000b1;&#x02009;4.66 versus Control: 55.0&#x02009;&#x000b1;&#x02009;5.21 uIU/mL) than the control group (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The Test 1 group exhibited significantly lower insulin AUC (Test 1: 46.2&#x02009;&#x000b1;&#x02009;5.32 versus Control: 55.0&#x02009;&#x000b1;&#x02009;5.21 uIU/mLxhr). We found significantly lower serum levels of C-peptide at 15&#x000a0;min (Test 1: 3.20&#x02009;&#x000b1;&#x02009;0.31, Test 2: 3.26&#x02009;&#x000b1;&#x02009;0.23 versus Control: 4.67&#x02009;&#x000b1;&#x02009;0.39&#x000a0;ng/dL) and 30&#x000a0;min (Test 1: 4.41&#x02009;&#x000b1;&#x02009;0.31 versus Control: 6.01&#x02009;&#x000b1;&#x02009;0.36&#x000a0;ng/dL) in the test groups compared to the control group.<fig id="Fig1"><label>Fig. 1</label><caption><p>Serum glucose levels in normal subjects. Values are expressed as the means&#x02009;&#x000b1;&#x02009;SEM. <italic>p</italic>-value tested using one-way analysis of variance (ANOVA) and Bonferroni methods</p></caption><graphic xlink:href="13063_2016_1261_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Glucose-related markers in normal subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th colspan="4">Normal subjects (n&#x02009;=&#x02009;25)</th></tr><tr><th/><th/><th>TEST (10:1)</th><th>TEST (15:1)</th><th>TEST (20:1)</th><th>Control</th></tr></thead><tbody><tr><td>Insulin<sup>a</sup>
</td><td>0&#x000a0;min</td><td>10.6&#x02009;&#x000b1;&#x02009;0.98</td><td>9.8&#x02009;&#x000b1;&#x02009;0.85</td><td>9.8&#x02009;&#x000b1;&#x02009;0.71</td><td>9.3&#x02009;&#x000b1;&#x02009;0.62</td></tr><tr><td>uIU/mL</td><td>15&#x000a0;min</td><td>28.3&#x02009;&#x000b1;&#x02009;5.19<sup>c</sup>
</td><td>24.8&#x02009;&#x000b1;&#x02009;3.47<sup>c</sup>
</td><td>31.4&#x02009;&#x000b1;&#x02009;4.05<sup>c</sup>
</td><td>56.6&#x02009;&#x000b1;&#x02009;7.18<sup>b</sup>
</td></tr><tr><td/><td>30&#x000a0;min</td><td>30.4&#x02009;&#x000b1;&#x02009;3.63<sup>c</sup>
</td><td>31.0&#x02009;&#x000b1;&#x02009;3.59<sup>c</sup>
</td><td>35.9&#x02009;&#x000b1;&#x02009;4.66<sup>c</sup>
</td><td>55.0&#x02009;&#x000b1;&#x02009;5.21<sup>b</sup>
</td></tr><tr><td/><td>60&#x000a0;min</td><td>25.8&#x02009;&#x000b1;&#x02009;2.93</td><td>29.1&#x02009;&#x000b1;&#x02009;2.35</td><td>24.9&#x02009;&#x000b1;&#x02009;2.54</td><td>29.0&#x02009;&#x000b1;&#x02009;3.05</td></tr><tr><td/><td>120&#x000a0;min</td><td>14.0&#x02009;&#x000b1;&#x02009;1.95<sup>b</sup>
</td><td>12.0&#x02009;&#x000b1;&#x02009;1.14</td><td>12.3&#x02009;&#x000b1;&#x02009;1.04</td><td>9.4&#x02009;&#x000b1;&#x02009;0.84<sup>c</sup>
</td></tr><tr><td colspan="2">Insulin AUC<sup>a</sup> (uIU/mLxhr)</td><td>46.2&#x02009;&#x000b1;&#x02009;5.32<sup>c</sup>
</td><td>46.8&#x02009;&#x000b1;&#x02009;3.50</td><td>47.4&#x02009;&#x000b1;&#x02009;3.77</td><td>62.4&#x02009;&#x000b1;&#x02009;4.91<sup>b</sup>
</td></tr><tr><td>C-peptide<sup>a</sup>
</td><td>0&#x000a0;min</td><td>1.89&#x02009;&#x000b1;&#x02009;0.17</td><td>1.92&#x02009;&#x000b1;&#x02009;0.16</td><td>1.82&#x02009;&#x000b1;&#x02009;0.15</td><td>1.92&#x02009;&#x000b1;&#x02009;0.14</td></tr><tr><td>(ng/mLxhr)</td><td>15&#x000a0;min</td><td>3.20&#x02009;&#x000b1;&#x02009;0.31<sup>c</sup>
</td><td>3.26&#x02009;&#x000b1;&#x02009;0.23<sup>c</sup>
</td><td>3.44&#x02009;&#x000b1;&#x02009;0.26</td><td>4.67&#x02009;&#x000b1;&#x02009;0.39<sup>b</sup>
</td></tr><tr><td/><td>30&#x000a0;min</td><td>4.41&#x02009;&#x000b1;&#x02009;0.31<sup>c</sup>
</td><td>4.62&#x02009;&#x000b1;&#x02009;0.32</td><td>4.82&#x02009;&#x000b1;&#x02009;0.42</td><td>6.01&#x02009;&#x000b1;&#x02009;0.36<sup>b</sup>
</td></tr><tr><td/><td>60&#x000a0;min</td><td>5.15&#x02009;&#x000b1;&#x02009;0.31</td><td>5.36&#x02009;&#x000b1;&#x02009;0.31</td><td>4.98&#x02009;&#x000b1;&#x02009;0.28</td><td>5.70&#x02009;&#x000b1;&#x02009;0.33</td></tr><tr><td/><td>120&#x000a0;min</td><td>3.62&#x02009;&#x000b1;&#x02009;0.22<sup>b</sup>
</td><td>3.49&#x02009;&#x000b1;&#x02009;0.24<sup>b</sup>
</td><td>3.20&#x02009;&#x000b1;&#x02009;0.21</td><td>2.69&#x02009;&#x000b1;&#x02009;0.19<sup>c</sup>
</td></tr><tr><td colspan="2">C-peptide AUC<sup>a</sup> (ng/mLxhr)</td><td>8.36&#x02009;&#x000b1;&#x02009;0.48</td><td>8.55&#x02009;&#x000b1;&#x02009;0.47</td><td>8.23&#x02009;&#x000b1;&#x02009;0.47</td><td>9.28&#x02009;&#x000b1;&#x02009;0.50</td></tr></tbody></table><table-wrap-foot><p>Mean&#x02009;&#x000b1;&#x02009;SEM. <sup>b,c</sup>Tested by ANOVA (Bonferroni)</p><p>
<sup>a</sup>Analyzed after log transformation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Comparisons of changes in serum glucose, insulin, and C-peptide levels in normal subjects</title><p>All test groups exhibited significantly lower changes in serum glucose levels at 15&#x02013;0 (Test 1: 17.4&#x02009;&#x000b1;&#x02009;2.28, Test 2: 16.4&#x02009;&#x000b1;&#x02009;2.23, Test 3: 20.5&#x02009;&#x000b1;&#x02009;2.75 versus Control: 32.9&#x02009;&#x000b1;&#x02009;3.24&#x000a0;mg/dL) and 30&#x02013;0 (Test 1: 28.9&#x02009;&#x000b1;&#x02009;2.07, Test 2: 28.8&#x02009;&#x000b1;&#x02009;2.58, Test 3: 31.0&#x02009;&#x000b1;&#x02009;3.03 versus Control: 44.9&#x02009;&#x000b1;&#x02009;3.02&#x000a0;mg/dL) compared to the control group (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). We also found significantly lower changes in serum insulin and C-peptide levels at 15&#x02013;0 and 30&#x02013;0 compared to the control group (data not shown).<fig id="Fig2"><label>Fig. 2</label><caption><p>Comparisons of changes in serum glucose levels in normal subjects. Values are expressed as the means&#x02009;&#x000b1;&#x02009;SEM. <italic>p</italic>-value tested using one-way analysis of variance (ANOVA) and Bonferroni methods</p></caption><graphic xlink:href="13063_2016_1261_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec15"><title>Effects of xylose consumption on postprandial glucose metabolism in hyperglycemic subjects</title><p>Hyperglycemic subjects (n&#x02009;=&#x02009;50) in the test groups exhibited a significant decrease in serum glucose levels at 30&#x000a0;min (Test 1: 149.6&#x02009;&#x000b1;&#x02009;3.44, Test 2: 152.5&#x02009;&#x000b1;&#x02009;3.56, Test 3: 158.8&#x02009;&#x000b1;&#x02009;3.99 versus Control: 176.4&#x02009;&#x000b1;&#x02009;5.18&#x000a0;mg/dL) compared to the control group (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). However, the Test 1 group exhibited a significant increase in serum glucose levels at 120&#x000a0;min compared to the control group. The glucose-related markers did not significantly differ between groups (Table <xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Serum glucose levels in hyperglycemic subjects. Values are expressed as the means&#x02009;&#x000b1;&#x02009;SEM. <italic>p</italic>-value tested using one-way analysis of variance (ANOVA) and Bonferroni methods</p></caption><graphic xlink:href="13063_2016_1261_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Glucose-related markers in hyperglycemic subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th colspan="4">Hyperglycemic subjects (n&#x02009;=&#x02009;50)</th></tr><tr><th/><th/><th>TEST (10:1)</th><th>TEST (15:1)</th><th>TEST (20:1)</th><th>Control</th></tr></thead><tbody><tr><td>insulin<sup>a</sup>
</td><td>0&#x000a0;min</td><td>10.0&#x02009;&#x000b1;&#x02009;0.77</td><td>10.4&#x02009;&#x000b1;&#x02009;1.13</td><td>10.9&#x02009;&#x000b1;&#x02009;1.39</td><td>9.5&#x02009;&#x000b1;&#x02009;0.57</td></tr><tr><td>uIU/mL</td><td>15&#x000a0;min</td><td>15.2&#x02009;&#x000b1;&#x02009;1.41</td><td>16.4&#x02009;&#x000b1;&#x02009;1.57</td><td>17.5&#x02009;&#x000b1;&#x02009;1.95</td><td>21.6&#x02009;&#x000b1;&#x02009;1.75</td></tr><tr><td/><td>30&#x000a0;min</td><td>24.5&#x02009;&#x000b1;&#x02009;2.31</td><td>24.6&#x02009;&#x000b1;&#x02009;2.72</td><td>25.2&#x02009;&#x000b1;&#x02009;2.48</td><td>33.3&#x02009;&#x000b1;&#x02009;3.19</td></tr><tr><td/><td>60&#x000a0;min</td><td>30.8&#x02009;&#x000b1;&#x02009;2.80</td><td>29.5&#x02009;&#x000b1;&#x02009;3.41</td><td>33.7&#x02009;&#x000b1;&#x02009;3.74</td><td>35.7&#x02009;&#x000b1;&#x02009;4.46</td></tr><tr><td/><td>120&#x000a0;min</td><td>19.7&#x02009;&#x000b1;&#x02009;3.59</td><td>20.2&#x02009;&#x000b1;&#x02009;3.48</td><td>21.7&#x02009;&#x000b1;&#x02009;4.36</td><td>16.1&#x02009;&#x000b1;&#x02009;2.74</td></tr><tr><td colspan="2">insulin AUC<sup>a</sup> (uIU/mLxhr)</td><td>47.2&#x02009;&#x000b1;&#x02009;4.69</td><td>46.9&#x02009;&#x000b1;&#x02009;5.34</td><td>51.8&#x02009;&#x000b1;&#x02009;6.24</td><td>53.9&#x02009;&#x000b1;&#x02009;5.58</td></tr><tr><td>C-peptide<sup>a</sup>
</td><td>0&#x000a0;min</td><td>2.43&#x02009;&#x000b1;&#x02009;0.13</td><td>2.40&#x02009;&#x000b1;&#x02009;0.14</td><td>2.53&#x02009;&#x000b1;&#x02009;0.16</td><td>2.42&#x02009;&#x000b1;&#x02009;0.12</td></tr><tr><td>(ng/mLxhr</td><td>15&#x000a0;min</td><td>3.12&#x02009;&#x000b1;&#x02009;0.14</td><td>3.21&#x02009;&#x000b1;&#x02009;0.14</td><td>3.39&#x02009;&#x000b1;&#x02009;0.17</td><td>3.72&#x02009;&#x000b1;&#x02009;0.19</td></tr><tr><td/><td>30&#x000a0;min</td><td>4.30&#x02009;&#x000b1;&#x02009;0.22</td><td>4.31&#x02009;&#x000b1;&#x02009;0.23</td><td>4.52&#x02009;&#x000b1;&#x02009;0.20</td><td>5.15&#x02009;&#x000b1;&#x02009;0.27</td></tr><tr><td/><td>60&#x000a0;min</td><td>5.87&#x02009;&#x000b1;&#x02009;0.27</td><td>5.89&#x02009;&#x000b1;&#x02009;0.30</td><td>6.37&#x02009;&#x000b1;&#x02009;0.29</td><td>6.51&#x02009;&#x000b1;&#x02009;0.39</td></tr><tr><td/><td>120&#x000a0;min</td><td>5.32&#x02009;&#x000b1;&#x02009;0.31</td><td>5.48&#x02009;&#x000b1;&#x02009;0.31</td><td>5.66&#x02009;&#x000b1;&#x02009;0.32</td><td>4.78&#x02009;&#x000b1;&#x02009;0.31</td></tr><tr><td colspan="2">C-peptide AUC<sup>a</sup> (ng/mLxhr)</td><td>9.76&#x02009;&#x000b1;&#x02009;0.44</td><td>9.87&#x02009;&#x000b1;&#x02009;0.46</td><td>10.46&#x02009;&#x000b1;&#x02009;0.46</td><td>10.44&#x02009;&#x000b1;&#x02009;0.53</td></tr></tbody></table><table-wrap-foot><p>Mean&#x02009;&#x000b1;&#x02009;SEM. Tested by ANOVA (Bonferroni)</p><p>
<sup>a</sup>Analyzed after log transformation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>Comparisons of changes in serum glucose, insulin, and C-peptide levels in hyperglycemic subjects</title><p>The test 1 group exhibited a significantly lower change in serum glucose levels at 15&#x02013;0 (Test 1: 17.3&#x02009;&#x000b1;&#x02009;2.11 versus Control: 27.4&#x02009;&#x000b1;&#x02009;2.79&#x000a0;mg/dL), and all test groups exhibited significantly lower changes in serum glucose levels at 30&#x02013;0 (Test 1: 39.4&#x02009;&#x000b1;&#x02009;2.47, Test 2: 44.8&#x02009;&#x000b1;&#x02009;2.48, Test 3: 47.5&#x02009;&#x000b1;&#x02009;2.55 versus Control: 66.5&#x02009;&#x000b1;&#x02009;4.05&#x000a0;mg/dL) than the control group (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). We also found significantly lower changes in serum insulin and C-peptide levels at 15&#x02013;0 and 30&#x02013;0 compared to the control group (data not shown).<fig id="Fig4"><label>Fig. 4</label><caption><p>Comparisons of changes in serum glucose levels in hyperglycemic subjects. Values are expressed as the means&#x02009;&#x000b1;&#x02009;SEM. <italic>p</italic>-value tested using one-way analysis of variance (ANOVA) and Bonferroni methods</p></caption><graphic xlink:href="13063_2016_1261_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec17"><title>Safety parameters of normal and prediabetic subjects</title><p>Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> shows the safety parameters of study subjects. Hyperglycemic subjects exhibited higher concentrations of GOT and GPT than normal subjects. However, these concentrations were within normal ranges.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Safety parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Normal subjects<break/>(n&#x02009;=&#x02009;25)</th><th>Hyperglycemic subjects<break/>(n&#x02009;=&#x02009;50)</th><th>
<italic>p</italic>-value</th></tr></thead><tbody><tr><td>WBC (&#x00445;10<sup>3</sup>/uL)</td><td char="&#x000b1;" align="char">5.59&#x02009;&#x000b1;&#x02009;0.25</td><td char="&#x000b1;" align="char">5.82&#x02009;&#x000b1;&#x02009;0.18</td><td>0.468</td></tr><tr><td>RBC (&#x00445;10<sup>3</sup>/uL)</td><td char="&#x000b1;" align="char">4.28&#x02009;&#x000b1;&#x02009;0.08</td><td char="&#x000b1;" align="char">4.33&#x02009;&#x000b1;&#x02009;0.05</td><td>0.558</td></tr><tr><td>HGB (g/dL)</td><td char="&#x000b1;" align="char">13.1&#x02009;&#x000b1;&#x02009;0.37</td><td char="&#x000b1;" align="char">13.4&#x02009;&#x000b1;&#x02009;0.14</td><td>0.543</td></tr><tr><td>HCT (%)</td><td char="&#x000b1;" align="char">40.7&#x02009;&#x000b1;&#x02009;1.08</td><td char="&#x000b1;" align="char">41.8&#x02009;&#x000b1;&#x02009;0.42</td><td>0.382</td></tr><tr><td>PLT (&#x00445;10<sup>3</sup>/mm<sup>3</sup>)</td><td char="&#x000b1;" align="char">256&#x02009;&#x000b1;&#x02009;13.3</td><td char="&#x000b1;" align="char">244&#x02009;&#x000b1;&#x02009;5.69</td><td>0.398</td></tr><tr><td>GOT (U/L)</td><td char="&#x000b1;" align="char">19.7&#x02009;&#x000b1;&#x02009;0.83</td><td char="&#x000b1;" align="char">25.3&#x02009;&#x000b1;&#x02009;1.09</td><td>&#x0003c;0.001</td></tr><tr><td>GPT (U/L)</td><td char="&#x000b1;" align="char">14.8&#x02009;&#x000b1;&#x02009;1.29</td><td char="&#x000b1;" align="char">25.3&#x02009;&#x000b1;&#x02009;2.44</td><td>&#x0003c;0.001</td></tr><tr><td>BUN (mg/dL)</td><td char="&#x000b1;" align="char">12.4&#x02009;&#x000b1;&#x02009;0.52</td><td char="&#x000b1;" align="char">14.2&#x02009;&#x000b1;&#x02009;0.55</td><td>0.028</td></tr><tr><td>Creatinine (mg/dL)</td><td char="&#x000b1;" align="char">0.76&#x02009;&#x000b1;&#x02009;0.03</td><td char="&#x000b1;" align="char">0.75&#x02009;&#x000b1;&#x02009;0.02</td><td>0.957</td></tr></tbody></table><table-wrap-foot><p>Mean&#x02009;&#x000b1;&#x02009;SEM. tested by Student <italic>t</italic>-test</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec18" sec-type="discussion"><title>Discussion</title><p>The present study determined the effects of xylose supplementation on postprandial glycemic responses in normal and hyperglycemic subjects. We investigated whether D-xylose less than 5&#x000a0;g per 50&#x000a0;g sucrose exerted beneficial effects on postprandial glycemic control. No adverse biochemical effects of D-xylose were observed in any subject during the entire study. We found that xylose supplementation may exhibit beneficial effects on postprandial glucose metabolism. Notable effects on postprandial glucose, insulin, and C-peptide levels were observed 15 and 30&#x000a0;min after the consumption of test drinks.</p><p>Xylose is a white crystalline sugar that exhibits approximately 60&#x000a0;% of the sweetness of sucrose. Various plants, including coconut and straw, are rich sources of D-xylose [<xref ref-type="bibr" rid="CR13">13</xref>]. Administration of a sucrose solution containing 10&#x000a0;% D-xylose (w/w) inhibited the rapid elevation of blood glucose in rats [<xref ref-type="bibr" rid="CR12">12</xref>]. Bae et al. reported that the consumption of sucrose drinks containing 10&#x000a0;% D-xylose (w/w) reduced GI 21.4&#x000a0;% and insulin secretion 21.3&#x000a0;% in healthy individuals [<xref ref-type="bibr" rid="CR13">13</xref>]. Bae et al. reported on the inhibitory effects of two different concentrations of xylose (5 and 7.5&#x000a0;g) on postprandial serum glucose and insulin concentrations in healthy subjects. However, our study examined the effect of three different concentration of xylose (2.5, 3.33, and 5&#x000a0;g) on postprandial serum glucose and insulin concentrations in subjects with normal glucose levels and hyperglycemia. We focused on the effect of low concentrations of xylose.</p><p>Some studies examined whether sucrose drinks with 5&#x000a0;% (w/w) D-xylose exerted beneficial effects on enhancing the glycemic response [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], but the number of subjects in these studies was too small (n&#x02009;=&#x02009;10 and n&#x02009;=&#x02009;13) to define the effect of D-xylose.</p><p>The homeostasis of glucose and other glucose-related metabolites, such as insulin and C-peptide, were the targets for the prevention of metabolic syndrome, such as type 2 diabetes and cardiovascular disease [<xref ref-type="bibr" rid="CR13">13</xref>]. Glucose absorption in the intestines should be adequately regulated to maintain glycemic homeostasis. Therefore, it is important that sucrase not rapidly hydrolyze sucrose into glucose and fructose. The effect of D-xylose occurs via the inhibition of sucrase activity in a non-competitive manner [<xref ref-type="bibr" rid="CR12">12</xref>]. Specifically, D-xylose inhibits sucrase activity by combining with the intermediate of sucrase and glucose, immediately after the dissociation of fructose [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>However, the ability of D-xylose to control the postprandial glycemic response may be difficult to sustain because a large amount of xylose is excreted rapidly in urine [<xref ref-type="bibr" rid="CR20">20</xref>]. Significant results in the prevention of the rapid increase in blood glucose, insulin, and C-peptide were observed at 15&#x000a0;min and 30&#x000a0;min, but this effect was not sustained at the later time points of 60&#x000a0;min and 120&#x000a0;min. Blood glucose levels were even higher 120&#x000a0;min after the consumption of xylose-containing drinks compared to a control drink, which may have occurred because secretion of the glucose-lowering hormone insulin was less stimulated by lower levels of serum glucose at 15&#x000a0;min and 30&#x000a0;min. However, xylose still effectively controlled postprandial glycemic because the AUCs of glucose, insulin, and C-peptide were significantly smaller after the consumption of all test drinks containing xylose.</p><p>One limitation of this study is that it evaluated the inhibitory effect of xylose on postprandial hyperglycemia after the intake of sucrose, but not complex carbohydrates. Our study period was also very short, and all of the test products were consumed once weekly. Therefore, further studies are required to identify how long-term xylose consumption affects glucose control and the effect of postprandial glucose on complex carbohydrates containing xylose (for example, muffins or sandwiches).</p><p>The present study suggests that xylose supplementation (5, 3.33, and 2.5&#x000a0;g) in drinks exhibits a beneficial effect on postprandial glycemic response and glucose-related biomarkers, including insulin and C-peptide levels, in subjects with normal glucose levels and impaired fasting glucose.</p></sec><sec id="Sec19" sec-type="conclusion"><title>Conclusions</title><p>We investigated whether D-xylose less than 5&#x000a0;g per 50&#x000a0;g sucrose exerted beneficial effects on postprandial glycemic control. We found that xylose supplementation may exert beneficial effects on postprandial glucose metabolism. Notable effects on postprandial glucose, insulin, and C-peptide levels were observed 15 and 30&#x000a0;min after the consumption of test drinks. Xylose supplementation may exert a beneficial effect on postprandial glycemic responses in subjects with normal glucose levels and prediabetes.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AUC</term><def><p>area under the curve</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>BP</term><def><p>blood pressure</p></def></def-item><def-item><term>FFA</term><def><p>free fatty acids</p></def></def-item><def-item><term>HbA1c</term><def><p>hemoglobin A1c</p></def></def-item><def-item><term>HDL</term><def><p>high-density lipoprotein</p></def></def-item><def-item><term>IFG</term><def><p>impaired fasting glucose</p></def></def-item><def-item><term>IGT</term><def><p>impaired glucose tolerance</p></def></def-item><def-item><term>LBM</term><def><p>lean body mass</p></def></def-item><def-item><term>LDL</term><def><p>low-density lipoprotein</p></def></def-item><def-item><term>OGTTs</term><def><p>oral glucose tolerance tests</p></def></def-item><def-item><term>T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item><def-item><term>TG</term><def><p>triglycerides</p></def></def-item><def-item><term>WHR</term><def><p>waist-to-hip ratio</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare no conflicts of interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>YJJ and JL conducted the research, analyzed the data, and wrote the paper. JHK, YKB, and JK designed the study, analyzed the data, and reviewed/edited the manuscript. SH and HYA contributed to data collection. JHL supervised the study. All authors approved the final manuscript for submission.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by the Bio-Synergy Research Project (NRF-2012M3A9C4048762, NRF-2013M3A9C4078159) of the Ministry of Science, ICT and Future Planning through the National Research Foundation.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Ministry of Health and Welfare. The fifth Korea National Health and Nutrition Examination Survey (KNHANES). Seoul: Ministry of Health and Welfare; 2010. p. 38&#x02013;45.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Ministry of Health and Welfare. The fifth Korea National Health and Nutrition Examination Survey (KNHANES). Seoul: Ministry of Health and Welfare; 2011. p. 445.</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Ministry of Health and Welfare. The fifth Korea National Health and Nutrition Examination Survey (KNHANES). Seoul: Ministry of Health and Welfare; 2012. p. 647.</mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Ministry of Health and Welfare. The fifth Korea National Health and Nutrition Examination Survey (KNHANES). Seoul: Ministry of Health and Welfare; 2013. p. 684.</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>JS</given-names></name></person-group><article-title>Postprandial hyperglycemia and cardiovascular disease</article-title><source>J Korean Diabetes</source><year>2012</year><volume>13</volume><issue>1</issue><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.4093/jkd.2012.13.1.18</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RJ</given-names></name><name><surname>Segal</surname><given-names>MS</given-names></name><name><surname>Sautin</surname><given-names>Y</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Feig</surname><given-names>DI</given-names></name><name><surname>Kang</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease</article-title><source>Am J Clin Nutr</source><year>2007</year><volume>86</volume><issue>4</issue><fpage>899</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">17921363</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>AL</given-names></name></person-group><source>Sweeteners: alternative</source><year>2000</year><publisher-loc>St. Paul, MN</publisher-loc><publisher-name>Eagan Press</publisher-name></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stemerdink</surname><given-names>BA</given-names></name><name><surname>van der Meere</surname><given-names>JJ</given-names></name><name><surname>van der Molen</surname><given-names>MW</given-names></name><name><surname>Kalverboer</surname><given-names>AF</given-names></name><name><surname>Hendrikx</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Information processing in patients with early and continuously-treated phenylketonuria</article-title><source>Eur J Pediatr</source><year>1995</year><volume>154</volume><issue>9</issue><fpage>739</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1007/BF02276719</pub-id><pub-id pub-id-type="pmid">8582426</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sliwowska</surname><given-names>JH</given-names></name><name><surname>Fergani</surname><given-names>C</given-names></name><name><surname>Gawa&#x00142;ek</surname><given-names>M</given-names></name><name><surname>Skowronska</surname><given-names>B</given-names></name><name><surname>Fichna</surname><given-names>P</given-names></name><name><surname>Lehman</surname><given-names>MN</given-names></name></person-group><article-title>Insulin: its role in the central control of reproduction</article-title><source>Physiol Behav</source><year>2014</year><volume>133</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2014.05.021</pub-id><pub-id pub-id-type="pmid">24874777</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>H</given-names></name><name><surname>Kimmerling</surname><given-names>G</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name><name><surname>Reaven</surname><given-names>GM</given-names></name></person-group><article-title>Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia</article-title><source>J Clin Invest</source><year>1975</year><volume>55</volume><issue>3</issue><fpage>454</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1172/JCI107951</pub-id><pub-id pub-id-type="pmid">1117064</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seri</surname><given-names>K</given-names></name><name><surname>Sanai</surname><given-names>K</given-names></name><name><surname>Matsuo</surname><given-names>N</given-names></name><name><surname>Kawakubo</surname><given-names>K</given-names></name><name><surname>Xue</surname><given-names>C</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name></person-group><article-title>L-arabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals</article-title><source>Metabolism</source><year>1996</year><volume>45</volume><issue>11</issue><fpage>1368</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/S0026-0495(96)90117-1</pub-id><pub-id pub-id-type="pmid">8931641</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Yoshimura</surname><given-names>Y</given-names></name><name><surname>Kunugita</surname><given-names>K</given-names></name></person-group><article-title>Sucrase inhibitory activity of D-xylose and effect on the elevation of blood glucose in rats</article-title><source>J Jpn Soc Nutr Food Sci</source><year>1996</year><volume>49</volume><issue>3</issue><fpage>157</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.4327/jsnfs.49.157</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>YJ</given-names></name><name><surname>Bak</surname><given-names>YK</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Sung</surname><given-names>MK</given-names></name></person-group><article-title>Coconut-derived D-xylose affects postprandial glucose and insulin responses in healthy individuals</article-title><source>Nutr Res Pract</source><year>2011</year><volume>5</volume><issue>6</issue><fpage>533</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4162/nrp.2011.5.6.533</pub-id><pub-id pub-id-type="pmid">22259678</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtin</surname><given-names>F</given-names></name><name><surname>Elbourne</surname><given-names>D</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Meta&#x02010;analysis combining parallel and cross&#x02010;over clinical trials. III: The issue of carry&#x02010;over</article-title><source>Stat Med</source><year>2002</year><volume>21</volume><issue>15</issue><fpage>2161</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1002/sim.1207</pub-id><pub-id pub-id-type="pmid">12210631</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Christian JL, Greger JL. Nutrition for Living. Redwood, CA: Benjamin Cummings; 1994. p. 111.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">The American Dietetic Association. Handbook of clinical dietetics. 2nd ed. New Haven: Yale University Press; 1992. p. 5&#x02013;39.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>DB</given-names></name><name><surname>Paultre</surname><given-names>F</given-names></name><name><surname>Maggio</surname><given-names>C</given-names></name><name><surname>Mezzitis</surname><given-names>N</given-names></name><name><surname>Pi-Sunyer</surname><given-names>FX</given-names></name></person-group><article-title>The use of area under curves in diabetes research</article-title><source>Diabetes Care</source><year>1995</year><volume>18</volume><fpage>245</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2337/diacare.18.2.245</pub-id><pub-id pub-id-type="pmid">7729306</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Kyung</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name></person-group><article-title>Study on the proper D-xylose concentration in sugar mixture to reduce glycemic index (GI) value in the human clinical model</article-title><source>Korean J Food Nutr</source><year>2012</year><volume>25</volume><issue>4</issue><fpage>787</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.9799/ksfan.2012.25.4.787</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Moon</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Yoon</surname><given-names>S</given-names></name><name><surname>Choe</surname><given-names>K</given-names></name><etal/></person-group><article-title>Glycemic index of sucrose with d-xylose (XF) in humans</article-title><source>Curr Top Nutraceutical Res</source><year>2013</year><volume>11</volume><fpage>35</fpage><lpage>9</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkohchi</surname><given-names>N</given-names></name><name><surname>Himukai</surname><given-names>M</given-names></name><name><surname>Igarashi</surname><given-names>Y</given-names></name><name><surname>Kasai</surname><given-names>M</given-names></name></person-group><article-title>Mechanism of D-xylose transport in human small intestine</article-title><source>J Pediatr Gastroenterol Nutr</source><year>1986</year><volume>5</volume><issue>3</issue><fpage>372</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/00005176-198605000-00006</pub-id><pub-id pub-id-type="pmid">3723257</pub-id></element-citation></ref></ref-list></back></article>